Stellaromics Rolls Out Pyxa 3D Spatial Multi‑Omics Platform at Premier U.S. and European Labs

Stellaromics, a pioneer in 3D spatial multi‑omics, announced the inaugural commercial deployments of its Pyxa® platform—the first solution enabling true 3D spatial multi‑omics in intact tissue—at the Icahn School of Medicine at Mount Sinai (New York City), CNAG in Barcelona, Karolinska Institutet in Stockholm, and Stanford University in Stanford, California. Pyxa resolves subcellular detail for hundreds of molecular targets simultaneously in tissue sections up to 100 µm thick, uncovering tissue architecture, cell‑cell interactions, and molecular gradients that are invisible with conventional thin‑section methods.

These installations follow Pyxa’s commercial debut at the Advances in Genome Biology and Technology (AGBT) conference in February 2026, marking Stellaromics’ shift from early‑access to worldwide availability.

“These laboratories embody the exact scientific vision Pyxa was created to serve,” said Todd Dickinson, Ph.D., CEO of Stellaromics. “Each team has spent years pushing the limits of tissue resolution and recognizes the necessity of moving beyond flat 2D analysis. Placing our first commercial systems in the hands of these leaders—spanning neuroscience, oncology, immunology, and large‑scale atlas projects—is deeply rewarding for our team and underscores the promise and demand for 3D spatial biology.”

The commercial placements are:

• Icahn School of Medicine at Mount Sinai (New York, NY): Robert Sebra, Ph.D., Professor of Genetics and Genomic Sciences and Director of the Center for Advanced Genomics Technology (CAGT). His group leverages bulk, single‑cell, spatial, and in‑situ genomics to pinpoint cellular niches that drive disease versus normal function, integrating transcriptomic, chromatin accessibility, proteomic, and epigenetic data from human cohorts and model systems.

  “Understanding disease increasingly hinges on cellular niches. We aim to identify which neighborhoods promote pathology and which preserve homeostasis,” said Dr. Sebra. “Because these niches are intrinsically three‑dimensional, we need to know not only what cells are doing but also where they sit relative to one another. We will combine these spatial relationships with multi‑omic data from human cohorts to elucidate how they shape the cellular architecture of disease.”

• CNAG (Centro Nacional de Análisis Genómico), Barcelona, Spain: Anna Pascual Reguant, Dr. rer. nat., Spatial Genomics Team Leader. The Spatial Genomics team explores how tissue architecture and spatially regulated gene expression influence immune responses and disease in cancer, chronic inflammation, infection, and autoimmunity, developing cutting‑edge spatial transcriptomics and tissue profiling technologies to decipher cellular organization and interactions that underlie pathology and enable next‑generation pathology.

  “Tissue function emerges from the spatial relationships between cells, which are inherently three‑dimensional,” said Dr. Pascual‑Reguant. “3D spatial transcriptomics lets us reconstruct tissue architecture and better understand how immune, epithelial, stromal, and vascular cells are organized within distinct niches. Capturing these interactions across intact volumes reveals how spatial organization drives immune responses, chronic inflammation, and malignant transformation—mechanisms hidden in two dimensions.”

  Holger Heyn, Ph.D., Single Cell Genomics Group Leader and Co‑chair of the Standards and Technologies Working Group of the Human Cell Atlas. Dr. Heyn’s group couples advanced single‑cell and spatial sequencing with computational method development to build reference atlases. A central aim of the group is translating these technologies into clinical tools for precision diagnostics and next‑generation immunotherapies in oncology and immune‑mediated disease.

  “Reference atlases are only as complete as the dimensions they capture,” said Dr. Heyn. “Adding true volumetric resolution to our single‑cell and spatial toolkit is an important step toward atlases that reflect how human tissues are actually organized and toward translating that organization into clinical applications in oncology and immune‑mediated disease.”

• Karolinska Institutet (Stockholm, Sweden): Michael Ratz, Ph.D., Department of Cell and Molecular Biology, who leads the Developmental Neurogenomics group. Dr. Ratz devised next‑generation clonal tracing that merges in‑vivo cellular barcoding with single‑cell and spatial transcriptomics to uncover lineage relationships underlying mammalian brain development. His lab uses these tools to decipher how neural circuits assemble and how mutations in risk genes contribute to neurodevelopmental disorders.

  “Using Pyxa, we aim to map the developing brain in three dimensions while simultaneously measuring the molecular identity and spatial context of individual cells,” said Dr. Ratz. “Combining our in‑vivo barcoding approach with true 3D spatial transcriptomics gives us a direct view of which cells share lineage, which neurons are linked within circuits, what cell types they are, where they are located, and how they are organized within the surrounding tissue.”

• Stanford University (Stanford, CA): Karl Deisseroth, M.D., Ph.D., D.H. Chen Foundation Professor of Bioengineering and Professor of Psychiatry and Behavioral Sciences, and Investigator of the Howard Hughes Medical Institute. The Deisseroth lab pioneered optogenetics and hydrogel‑tissue chemistry—including CLARITY and STARmap, the foundational chemistry behind Pyxa—and applies these methods to map cell types, connections, and circuit dynamics that drive behavior and neuropsychiatric disease.

“Commercial placements at institutions of this caliber, together with our beta sites, validate both the technology and our global support capability,” said Veronica Mankinen, Senior Vice President of Global Commercial Operations at Stellaromics. “Since our launch at AGBT, we have observed growing momentum across academia and biopharma, with an expanding installed base throughout North America and Europe, and we are committed to helping researchers see how true 3D spatial multi‑omics can push their work beyond traditional approaches.”

“The systems announced today add to the Pyxa instruments already operating at leading U.S. and U.K. research sites under our beta program, where early oncology and neuroscience datasets demonstrate the insights volumetric spatial analysis provides that thin sections miss. Stellaromics will continue to broaden Pyxa availability across North America, Europe, and Asia‑Pacific through 2026, with new applications, panels, and analysis tools planned throughout the year. Researchers can view Pyxa data at forthcoming scientific gatherings, including the European Society for Spatial Biology (ESSB) meeting and the Society for Neuroscience’s (SfN) Neuroscience 2026 annual meeting.”

Source link